The Effect of Related Blood Markers on Diabetic Peripheral Neuropathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

1400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-01

Study Completion Date

2025-01-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to explore the relationship between related blood indicators and diabetic peripheral neuropathy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Related Blood Markers on Diabetic Peripheral Neuropathy

NCT06041412

Diabetic Peripheral Neuropathy

UNKNOWN

Diagnostic Accuracy of Quantitative Neuropad Test for Diabetic Peripheral Neuropathy

NCT05347420

Diabetic Peripheral Neuropathy

UNKNOWN

Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy

NCT06131918

Peripheral Diabetic Neuropathy

COMPLETED PHASE2

Microvascular Dysfunction in Diabetic Peripheral Neuropathy

NCT05118217

Diabetic Peripheral Neuropathy Painful Diabetic Neuropathy

UNKNOWN

A Study on the Safety and Efficacy of Nitric Oxide Gel in Subjects With Painful Diabetic Neuropathy

NCT01633086

Neuropathic Pain

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center(about five), randomized, double-blind, placebo-controlled clinical trial with over 1000 subjects.Clinical data were collected by consulting the patient's electronic history. The data included demographic information, blood biochemical markers and electromyography. All participants provided their written informed consent to participate in this study.The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University(KY-2022-R009).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Peripheral Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

diabetic peripheral neuropathy group with hypoglycemic or lipid-lowering drugs.

Patients with type 2 diabetic peripheral neuropathy were categorized into the diabetic peripheral neuropathy group with hypoglycemic or lipid-lowering drugs group.The group treated with specific drug,like hypoglycemic or lipid-lowering drugs.

Group Type EXPERIMENTAL

hypoglycemic Agents(metformin)

Intervention Type DRUG

patients treated with hypoglycemic Agents(metformin)

lipid-lowering drug(Statin)

Intervention Type DRUG

patients treated with lipid-lowering drug(Statin)

diabetic peripheral neuropathy group without hypoglycemic or lipid-lowering drugs.

Patients with type 2 diabetic peripheral neuropathy were categorized into the diabetic peripheral neuropathy group without hypoglycemic or lipid-lowering drugs group.No hypoglycemic or lipid-lowering drugs were used in this group.

Group Type NO_INTERVENTION

No interventions assigned to this group

Diabetic group with hypoglycemic or lipid-lowering drugs.

Patients with type 2 diabetes mellitus but not with diabetic peripheral neuropathy were distributed into the Diabetic group with hypoglycemic or lipid-lowering drugs group. group.The group treated with specific drug,like hypoglycemic or lipid-lowering drugs.

Group Type EXPERIMENTAL

hypoglycemic Agents(metformin)

Intervention Type DRUG

patients treated with hypoglycemic Agents(metformin)

lipid-lowering drug(Statin)

Intervention Type DRUG

patients treated with lipid-lowering drug(Statin)

Diabetic group without hypoglycemic or lipid-lowering drugs.

Patients with type 2 diabetes mellitus but not with diabetic peripheral neuropathy were distributed into the Diabetic group without hypoglycemic or lipid-lowering drugs group.No hypoglycemic or lipid-lowering drugs were used in this group.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

hypoglycemic Agents(metformin)

patients treated with hypoglycemic Agents(metformin)

Intervention Type DRUG

lipid-lowering drug(Statin)

patients treated with lipid-lowering drug(Statin)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients who had undergone nerve conduction examination by electromyography(EMG).

Exclusion Criteria

* pregnancy and lactation; chronic liver disease, kidney disease, arrhythmias, malignant diseases, severe respiratory diseases, heart failure, and acute infections;
* patients with alcohol abuse; history of Autoimmune liver disease, liver disease or abnormal liver function at baseline;
* parathyroid diseases (including hyperthyroidism and hypothyroidism);
* pancreatitis, pancreatectomy or any transplant;
* patients with malignancy and any serious concomitant disease limit the existence of life expectancy

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes